CompletedNot Applicable

Comorbidity-Based Propranolol Use in Pediatric Migraine

Turkey (Türkiye)488 participantsStarted 2021-01-01

Plain-language summary

This observational retrospective cohort study aims to identify clinical and biochemical predictors of response to propranolol prophylaxis in pediatric migraine. A total of 178 children diagnosed with migraine between 2021 and 2023 were evaluated based on headache-related disability (PedMIDAS) and pain severity (VAS). Patients were treated either with behavioral therapy or propranolol (1-3 mg/kg/day) for 3 months.

Who can participate

Age range2 Years – 19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children aged 0-20 years * Diagnosed with primary headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) * Clinical and/or neurological evaluation consistent with primary headache * Completed baseline PedMIDAS and VAS assessments * Available for 3-month follow-up after initiation of treatment Exclusion Criteria: * Diagnosis of secondary headache, based on clinical history, family history, neurological examination, or laboratory/imaging findings * Failure to meet ICHD-3 diagnostic criteria for primary headache * Presence of structural brain lesions or other neurological disorders * Chronic systemic illness or current use of other migraine prophylactic medications * Incomplete data or loss to follow-up within the 3-month period

What they're measuring

Pediatric Migraine Disability Assessment Scale (PedMIDAS) Score

Timeframe: Baseline to 3 months after treatment

Trial details

NCT IDNCT07103031

SponsorKayseri University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Pediatric Migraine trials